BGB-283
BGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM) ; inhibits recombinant BRAFV600E with IC50 of 23 nM; also inhibits EGFR and EGFR T790M/L858R with IC50 of 29 nM and 495 nM respectively; potently inhibits BRAF (V600E) -activated ERK phosphorylation and cell proliferation in vitro; shows tumor growth inhibition in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF (V600E) mutation.Colon Cancer Preclinical.
Product Specifications
CAS Number
1446090-77-2
Product Name Alternative
Lifirafenib | BGB 283 | BGB283
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 125 mg/mL
Smiles
[H][C@@]1 (C2=CC (OC3=C (CCC4=O) C (N4) =NC=C3) =CC=C2O[C@]51[H]) [C@@H]5C6=NC7=CC=C (C=C7N6) C (F) (F) F
Molecular Formula
C25H17F3N4O3
Molecular Weight
478.4227
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CRLS1, CT (CRLS1, C20orf155, CLS1, Cardiolipin synthase, Protein GCD10 homolog) (MaxLight 750)
CRLS1, CT (CRLS1, C20orf155, CLS1, Cardiolipin synthase, Protein GCD10 homolog) (MaxLight 750)